Cargando…

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae

INTRODUCTION: Drug efflux pumps are critical for resistance in Gram-negative organisms, but there are limited data on the role they play in decreased susceptibility to β-lactam/β-lactamase inhibitor combinations. In this study, we aimed to investigate the impact of efflux pump AcrAB on piperacillin–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junjie, Xu, Qingqing, Ogurek, Sean, Li, Ziqiang, Wang, Peiyun, Xie, Qing, Sheng, Zike, Wang, Minggui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705282/ https://www.ncbi.nlm.nih.gov/pubmed/33273833 http://dx.doi.org/10.2147/IDR.S279020

Ejemplares similares

Minimal impact of selective susceptibility reporting on the use of piperacillin-tazobactam for Escherichia coli and Klebsiella bacteremia
por: Zahlanie, Yorgo, et al.
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible
por: Baker, Thomas M, et al.
Publicado: (2018)

1061. Decreased Utilization of Piperacillin–Tazobactam for Escherichia coli and Klebsiella Bacteremia due to Selective Susceptibility Reporting
por: Zahlanie, Yorgo, et al.
Publicado: (2019)

Structure of the AcrAB-TolC multidrug efflux pump
por: Du, Dijun, et al.
Publicado: (2014)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam
por: Garneau, Julian R, et al.
Publicado: (2014)

Expression of the AcrAB Components of the AcrAB-TolC Multidrug Efflux Pump of Yersinia enterocolitica Is Subject to Dual Regulation by OmpR
por: Raczkowska, Adrianna, et al.
Publicado: (2015)

Contribution of AcrAB efflux pump to ciprofloxacin resistance in Klebsiella pneumoniae isolated from burn patients
por: Pakzad, Iraj, et al.
Publicado: (2013)

Contribution of the efflux pump AcrAB-TolC to the tolerance of chlorhexidine and other biocides in Klebsiella spp.
por: Wand, Matthew E., et al.
Publicado: (2022)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
por: Huang, Weihua, et al.
Publicado: (2020)

2407. Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp.
por: Suseno, Mira, et al.
Publicado: (2018)

Rapid Detection of Piperacillin-Tazobactam Resistance in Klebsiella pneumoniae and Escherichia coli
por: Ortiz de la Rosa, José Manuel, et al.
Publicado: (2023)

First Emergence of acrAB and oqxAB Mediated Tigecycline Resistance in Clinical Isolates of Klebsiella pneumoniae Pre-Dating the Use of Tigecycline in a Chinese Hospital
por: Zhong, Xue, et al.
Publicado: (2014)

AcrAB-TolC efflux pump system plays a role in carbapenem non-susceptibility in Escherichia coli
por: Chetri, Shiela, et al.
Publicado: (2019)

Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

1809. Treatment Outcomes in Piperacillin-tazobactam Non-susceptible (TZP-NS)/Ceftriaxone Susceptible (CRO-S) Infections
por: Dubrovskaya, Yanina, et al.
Publicado: (2022)

421. In vitro and in vivo synergistic antimicrobial activities of the combinations of meropenem, colistin, tigecycline, and ceftolozane/tazobactam against carbapenem-resistant Klebsiella pneumoniae
por: Yoon, Young Kyung, et al.
Publicado: (2022)

Pimozide Inhibits the AcrAB-TolC Efflux Pump in Escherichia coli
por: Bohnert, Jürgen A, et al.
Publicado: (2013)

Genetic inactivation of acrAB or inhibition of efflux induces expression of ramA
por: Lawler, A. J., et al.
Publicado: (2013)

In situ structure and assembly of the multidrug efflux pump AcrAB-TolC
por: Shi, Xiaodong, et al.
Publicado: (2019)

An allosteric transport mechanism for the AcrAB-TolC multidrug efflux pump
por: Wang, Zhao, et al.
Publicado: (2017)

1414. Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes
por: Custodio, Marco, et al.
Publicado: (2018)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
por: Kauf, Teresa L, et al.
Publicado: (2017)

Activity of Ceftolozane-Tazobactam Against Global Pseudomonas Aeruginosa and Non-Susceptible Phenotypes: SMART 2016
por: Lob, Sibylle, et al.
Publicado: (2017)

305. Prevalence of Ceftriaxone Susceptible, Piperacillin-tazobactam Non-susceptible Escherichia coli Bacteremia in Patients with Hematologic Malignancy
por: Spitznogle, Sarah L, et al.
Publicado: (2020)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Bigseth, Robert Strengen, et al.
Publicado: (2022)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_07lb6grcj0ap4t9e1upjb8d7mh